Consensus CureVac N.V.

Equities

CVAC

NL0015436031

Real-time Estimate Cboe BZX Other stock markets 11:35:32 2024-04-26 am EDT			5-day change	1st Jan Change
2.305 ^USD	-0.22%		-5.74%	-45.37%

Apr. 25	Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	MT
Apr. 25	CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on CureVac N.V.

Price target over the last 5 years

History of analyst recommendation changes

fedb94f197be8d8f02eebbe5e8272.XDYvWe_4YO06hhbvF2mL_nHdHuJfOQHeur0wvgErfOY.BQFbFZqrOYUN4FewUz7SsDuaf6svUTW9w_xp7FZgMKEzB2oytr9Z2QL2Ig~50c424ecaa8ccc99ce4898f602e1d1ba

Analyst Recommendations on CureVac N.V.

Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	Apr. 25	MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	Dec. 22	MT
CUREVAC : An untrimmed pipeline becomes costly	Nov. 29
CUREVAC : Unchanged cash drain	Nov. 28
CUREVAC : A missed opportunity	23-08-21
CUREVAC : Higher losses expected in future	23-07-25
CUREVAC : Some glimpse of positive pipeline developments	23-06-21
SVB Securities Initiates CureVac at Outperform With $13 Price Target	23-06-08	MT
CUREVAC : Runway prolonged	23-05-30
CUREVAC : One big point despite many misses	23-05-02
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating	23-04-26	MT
CUREVAC : Everything hangs on the decision of the new CEO	23-03-16
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8	23-01-19	MT
CUREVAC : UBS raises its recommendation to Buy	23-01-19	ZD
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
Jefferies Upgrades CureVac to Buy From Hold	23-01-09	MT
CUREVAC : Berenberg reaffirms its Buy rating	23-01-06	ZD
UBS Initiates Coverage on CureVac With Neutral Rating, $8 Price Target	22-12-20	MT
JMP Securities Adjusts Price Target on CureVac to $34 From $37, Maintains Market Outperform Rating	22-11-17	MT
Berenberg Bank Adjusts CureVac Price Target to $22 From $45, Maintains Buy Rating	22-11-17	MT
Roche’s Alzheimer’s failure has sector-wide implications	22-11-14
Berenberg US CEO Conference	22-11-01	FA
Berenberg/Goldman Sachs German Corporate Conference	22-09-19	FA
Berenberg Bank Adjusts CureVac's Price Target to $45 From $52, Maintains Buy Rating	22-08-19	MT
Berenberg Bank USA Conference	22-05-22	FA

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.156 EUR

Average target price

13.24 EUR

Spread / Average Target

+514.22%

High Price Target

16.84 EUR

Spread / Highest target

+681.12%

Low Price Target

7.298 EUR

Spread / Lowest Target

+238.44%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CureVac N.V.

Leerink Partners
Kempen
alphavalue	Martin Schnee
SVB Securities LLC
JMP Securities
UBS
Jefferies & Co.
BERENBERG	Zhiqiang Shu
Berenberg Bank
BofA Securities
Deutsche Bank Securities
Guggenheim

Ratings for CureVac N.V.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar